Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug by �씠�룞湲�
Research Article
Molecular Mechanism of Local Drug Delivery with
Paclitaxel-Eluting Membranes in Biliary and Pancreatic Cancer:
New Application for an Old Drug
Sookhee Bang,1 Sung Ill Jang,2 Su Yeon Lee,1 Yi-Yong Baek,1 Jieun Yun,3 Soo Jin Oh,3
Chang Woo Lee,3 Eun Ae Jo,4 Kun Na,5 Sugeun Yang,6 Don Haeng Lee,7 and Dong Ki Lee1
1Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 712 Eonjuro, Gangnam-gu,
Seoul 135-720, Republic of Korea
2Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea
3Department of Bioevaluation Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon, Republic of Korea
4Department of Research and Development, Taewoong Medical Co., Gimpo, Republic of Korea
5Department of Biotechnology, The Catholic University, Bucheon, Republic of Korea
6Department of New Drug Development, School of Medicine, Inha University, Incheon, Republic of Korea
7Department of Internal Medicine, School of Medicine, Inha University, Incheon, Republic of Korea
Correspondence should be addressed to Dong Ki Lee; dklee@yuhs.ac
Received 18 August 2014; Revised 6 October 2014; Accepted 7 October 2014
Academic Editor: Chunping Jiang
Copyright © 2015 Sookhee Bang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Implantation of self-expanding metal stents (SEMS) is palliation for patients suffering from inoperable malignant obstructions
associated with biliary and pancreatic cancers. Chemotherapeutic agent-eluting stents have been developed because SEMS
are susceptible to occlusion by tumor in-growth. We reported recently that paclitaxel-eluting SEMS provide enhanced local
drug delivery in an animal model. However, little is known about the molecular mechanisms by which paclitaxel-eluting
stents attenuate tumor growth. We investigated the signal transduction pathways underlying the antiproliferative effects of
a paclitaxel-eluting membrane (PEM) implanted in pancreatic/cholangiocarcinoma tumor bearing nude mice. Molecular and
cellular alterations were analyzed in the PEM-implanted pancreatic/cholangiocarcinoma xenograft tumors by Western blot,
immunoprecipitation, and immunofluorescence. The quantities of paclitaxel released into the tumor and plasma were determined
by liquid chromatography-tandem mass spectroscopy. Paclitaxel from the PEM and its diffusion into the tumor inhibited
angiogenesis, which involved suppression of mammalian target of rapamycin (mTOR) through regulation of hypoxia inducible
factor (HIF-1) and increased apoptosis. Moreover, implantation of the PEM inhibited tumor-stromal interaction-related expression
of proteins such as CD44, SPARC, matrix metalloproteinase-2, and vimentin. Local delivery of paclitaxel from a PEM inhibited
growth of pancreatic/cholangiocarcinoma tumors in nude mice by suppressing angiogenesis via the mTOR and inducing apoptosis
signal pathway.
1. Introduction
Malignant biliary obstruction is associated with biliary can-
cer, pancreatic cancer, and other local cancers. Endoscopic
biliary drainage with self-expanding metal stents (SEMS) is
the treatment of choice for palliation in patients with an
unresectable biliary obstruction [1, 2]. A metallic stent cov-
eredwith a paclitaxel-incorporatedmembrane (MSCPM) has
been developed to promote the antitumor effect against extra-
hepatic cholangiocarcinoma, spreading along the bile duct
wall, and to sustain stent patency by inhibiting tumor in-
growth into the SEMS [3–7]. A double-layered MSCPM has
been developed, which has a bile resistant inner layer of poly-
tetrafluoroethylene and an outer layer of drug-containing
polyurethane with pluronic F-127, a surfactant for effective
drug delivery. We have reported that paclitaxel-eluting stents
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with 10% pluronic F-127 (MSCPM-II; TaewoongMedical Co.,
Gimpo, Korea) are safe and provide enhanced local drug
delivery (LDD) in an animal model [8]. MSCPM-II is cur-
rently awaiting human application.
The chemotherapeutic mechanism of paclitaxel is to sta-
bilize microtubules during mitosis and to arrest cell growth
[9, 10]. In addition, paclitaxel has antiangiogenic and anti-
metastatic properties [11, 12]. The clinical application of
paclitaxel in cancer treatment is considerably limited due
to its poor availability from systemic administration [13].
Therefore, many efforts have been made to develop an alter-
native paclitaxel delivery system to increase its availability
at tumor sites and to maximize therapeutic efficacy while
minimizing side effects [14]. Furthermore, paclitaxel is useful
for locoregional cancer therapy because it has good pharma-
cokinetic characteristics (e.g., lipophilic and rapid cellular
uptake) [15]. Paclitaxel-eluting covered metal stents, which
were introduced recently, may prevent occlusion from tumor
in-growth due to the antitumor effect of paclitaxel. The
diversemolecular signaling pathways generated by paclitaxel-
eluting stents that exert antiproliferative, proapoptotic, and
antiangiogenic effects in tumors have not been identified.
In the present study, we report a number of molecular
pathways and cellular mechanisms that are associated with
subtumoral implantation of a paclitaxel-eluting membrane
(PEM), which is of identical composition to the outer layer
of MSCPM-II that inhibits tumor growth. We analyzed the
protein profile by immunoblot/immunoprecipitation anal-
yses and validated the profile by immunofluorescence in
pancreatic and cholangiocarcinoma xenograft tumors. We
then explored the antiproliferative/apoptotic/antiangiogenic
effects of the PEM, a clinically relevant drug-eluting stent
identified in our study, to reveal its potential therapeutic
significance for inoperable malignant biliary obstructions.
2. Materials and Methods
2.1. Cell Lines and Antibodies. The human pancreatic cancer
cell lines PANC-1 and CFPAC-1 were cultured in Dulbecco’s
modified Eagle’s medium and the cholangiocarcinoma cell
linesHuCCT-1 and SCKwere cultured inRPMI-1640. PANC-
1 and CFPAC-1 cells were purchased from the ATCC (Manas-
sas, VA, USA). HuCCT-1 and SCK cells were procured from
the Health Science Research Resources Bank (Osaka, Japan)
and Dr. Dae-Ghon Kim of Chonbuk National University
Medical School and Hospital (Jeonju, Korea), respectively.
All cell lines were maintained in a humidified incubator at
37∘C with 5% CO
2
. Antibodies against S6K, phospho-S6K,
S6, phospho-S6, 4EBP1, phospho-4EBP1, cleaved caspase-3,
CHOP, Bax, Bim, BCl-2, cyclin B1, HIF-1𝛽, CD44, SPARC,
vimentin, and GAPDH were obtained from Cell Signaling
Technology. CD-31 and VEGF were purchased from Abcam
(Cambridge, MA, USA). HIF-1𝛼, VEFGR2/Flk-1, and MMP-
2 were obtained from Santa Cruz Biotechnology.
2.2. Tumor Xenograft and Treatment. Female 6–8-week-old
athymic nude mice were purchased fromOrient Bio (Kyung-
gido, Korea) for subcutaneous xenografts. To establish the
tumor xenograft model, 2 × 106 cells were suspended in
200𝜇L plain growth media (DMEM or RPMI-1640) and
injected subcutaneously into spaces under the dorsal skin.
Tumors were measured every other day using calipers, and
their volumes were calculated by the following formula: 0.5 ×
length × width2. The animal’s body weight was monitored
every other day. When tumor volume reached 100mm3, the
mice were anesthetized with a mixture of Zoletil (30mg/kg)
and Rompun (10mg/kg) i.p., and the PEMs were surgically
implanted underneath the tumors. All animal studies were
conducted in compliance with the policy of the animal
care and use committee of the Korean Research Institute of
Bioscience and Biotechnology.
2.3. Preparation of Paclitaxel-Eluting Membrane. PEMs were
fabricated using a mold. Briefly, 400mg of polymer was
dissolved in 10mL of tetrahydrofuran (THF). Pluronic F-127
(Plu; 40mg) and 1–10wt% paclitaxel (PTX, 4–40mg) were
dissolved inTHFand then added to the PU/THF solution and
mixed by vortex and sonication. A 200 𝜇L aliquot of the mix-
ture was poured into a dish-shape Teflon mold.The air-dried
paclitaxel-eluting dish-shaped membranes were carefully
peeled off the Teflon mold. Additionally, the PU membrane
without paclitaxel and Plu (control) or Plu alone (control +
Plu) was fabricated by the samemethod as the in vivo control.
2.4. Immunoprecipitation and Immunoblot Analyses. Tumors
were minced coarsely and homogenized with lysis buffer
containing 100mM Tris (pH 7.4), 150mM NaCl, 1% Triton
X-100, 15% glycerol, 1mM PMSF, phosphatase inhibitor
mixtures 2 and 3 (Sigma, St. Louis, MO, USA), and a
protease inhibitor mixture (Sigma). The homogenates were
centrifuged at 14,000 rpm and 4∘C, and the supernatants were
used. Protein concentration was estimated using the Bio-Rad
protein assay (Bio-Rad,Munich, Germany). For immunopre-
cipitation, tumor lysate protein (1mg) was incubated with
2 𝜇g of anti-Bax or anti-Raptor antibodies (Cell Signaling
Technology, Danvers, MA, USA) as indicated for 16 h at 4∘C
and precipitated with 50𝜇L of TrueBlot anti-rabbit Ig IP
beads (eBioscience, San Diego, CA, USA) for an additional
3 h.Then, the sampleswerewashedfive timeswith lysis buffer,
and SDS-loading sample buffer was added. Immunopre-
cipitates and total tumor lysates (30𝜇g) were separated on
NuPage 4–12% gradient Bis-Tris gels (Invitrogen, Grand
Island, NY, USA). Following sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, the proteins were trans-
ferred to nitrocellulose membranes (Bio-Rad). The blots
were blocked in TBS with 0.1% Tween-20 buffer (TBST)
containing 5% nonfat dry milk for 1 h at room temperature.
The membrane was incubated overnight at 4∘C with one of
the following primary antibodies. After repeated washings
with TBST, the membranes were incubated with goat anti-
mouse IgG-horse radish peroxidase (HRP) or goat anti-rabbit
IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 1 h at room temperature before washing again with TBST.
TrueBlot anti-rabbit Ig HRP-conjugated secondary antibody
(eBioscience) was used to detect coimmunoprecipitates
of Bim or hypoxia-inducible factor (HIF)-1𝛼 blots with
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a chemiluminescence reagent (Bio-Rad). GAPDH expression
levels were used to normalize protein loading. The sizes of
the molecular weight markers (in kilodaltons) are indicated
on the left. All critical blots and immunoprecipitation exper-
iments were repeated at least three times.
2.5. Immunofluorescence from Tumor Samples. Tumors were
immersed in OCT compound (Leica Biosystems, Richmond,
CA, USA) and frozen in liquid nitrogen. The sections (5 𝜇m)
were permeabilized, blocked with 10% goat antiserum and
0.25% Triton X-100 in PBS to avoid nonspecific binding for
60min, and subsequently incubated with rabbit anti-cleaved
caspase-3 (1 : 400), rabbit anti-CD31 (1 : 400), or mouse mon-
oclonal anti-vascular endothelial growth factor receptor-
2 (VEGFR2) (1 : 400) antibodies. Next, the sections were
washed and further incubated with the corresponding Alexa-
488-conjugated secondary antibodies (Invitrogen). Nuclei
were stained with DAPI (Invitrogen). Fluorescence images
were acquired using an Axiovert 135 microscope (Carl Zeiss,
Thornwood, NY, USA).
2.6. Immunohistochemistry. The tumors were removed and
fixed in 10% phosphate-buffered formaldehyde at room tem-
perature until sectioning. Briefly, all tumors were serially
sectioned and tissue sections (5𝜇m thick) obtained from
the paraffin blocks were stained with hematoxylin and eosin
(H&E) using standard histological techniques.
2.7. Measurement of Paclitaxel Content in Tumor Tissue by
Liquid Chromatography-TandemMass Spectrometry (LC-MS/
MS). Tumors and plasma samples were prepared and pacli-
taxel concentrations were analyzed by LC-MS/MS. Briefly,
the samples were extracted with 100% acetonitrile containing
carbamazepine as an internal standard, and chromatography
was conducted on an Xterra C18 column (50 × 2.1mm i.d.,
5 𝜇m, Waters, Milford, MA, USA) with a SecurityGuard C
18
guard column (2.0 × 4.0mm i.d., Phenomenex, Torrance,
CA, USA) maintained at room temperature. The mobile
phase was 95% v/v solvent A (deionized water containing
0.1% v/v formic acid)/5% v/v solvent B (acetonitrile contain-
ing 0.1% v/v formic acid) at a flow rate of 0.4mL/min. A linear
gradient of the two solvents was used: start at 95%A and hold
for 0.5min, ramp to 5% A to 0.6min, and hold until 4min.
The flow rate was 0.4mL/min throughout the gradient. The
retention times of paclitaxel and the internal standard (IS)
were 3.0 and 2.8min, respectively.The electrospray ionization
source was operated at 5500V and 550∘C. The samples were
analyzed via multiple reaction monitoring. The monitoring
ions were set asm/z 876 → 308 for paclitaxel andm/z 237 →
194 for the IS.The scandwell timewas 0.1 sec for each channel.
Acquisition and analysis of data were performed using the
Analyst software ver. 1.5.2 (Applied Biosystems, Foster City,
CA, USA).
2.8. Statistical Analysis. Data are presented as means ±
standard deviations. The statistical analysis was performed
using Student’s t-test when appropriate. Significance was
established when 𝑃 < .05. All experiments were performed
a minimum of three times.
3. Results
3.1. The PEM Reduces Growth of Pancreatic/Biliary Xenograft
Tumors in Nude Mice via Induction of Apoptosis and Endo-
plasmic Reticulum- (ER-) Stress in Tumors. We have demon-
strated previously that paclitaxel-eluting SEMS containing
10% pluronic acid F-127 (MSCPM-II) provide enhanced LDD
to the porcine bile duct [8]. Hence, we examined the molecu-
larmechanismunderlying the antiproliferative effects of PEM
implantation in tumor-bearing nudemice. Xenografted nude
mice were implantedwith pluronic acid alone (control + Plu),
5% and 10% paclitaxel and pluronic acid (PTX + Plu)-eluting
membrane (PEM), or a bare membrane (control) for 15–20
days. First, we determinedwhether PEM implantation caused
tumor shrinkage.Weobserved that the PEMwas clearly effec-
tive for reducing tumor growth, compared with the control
(bare membrane or Plu only) (Figure 1(a), Supplementary
Figures S1 and S2 in supplementary material available online
at http://dx.doi.org/10.1155/2015/568981). Moreover, no host
toxicity was observed (data not shown). The drug-release
study showed a 10-fold greater concentration of paclitaxel in
tumors proximal to the PEM than in those distal to the PEM
15 days after implantation, whereas plasma concentrations of
paclitaxel following membrane implantation remained less
than the lower limit of quantitation (Figure 1(b)). Paclitaxel
easily penetrated the cells of the tumor mass due to its
lipophilic properties, which led to chronic retention of the
drug in the tumor tissue. This result indicates that local
delivery of PTX to tumor tissue is effective for reducing tumor
growth without detectable systemic levels (Supplementary
Figure S3). The significance of PEM-induced inhibition of
tumor growth andwhether it is related to cellular apoptosis or
necrosis should be further investigated.TheH&E histological
analysis showed increased necrosis in the PEM-implanted
tumors compared with the control (Figure 1(c)). We exam-
ined the effect of the PEM on expression of apoptosis-related
proteins in tumor lysates to explore the link between tumor
regression and induction of apoptosis by the PEM. Because
the Bcl-2 family protein members are major regulators of the
mitochondrial apoptotic pathway, we examined the expres-
sion of Bcl-2 family proteins in response to PEM implantation
into tumors. As shown in Figure 1(d), expression of the
proapoptotic proteins Bax [16] and Bim [17] increased in
tumors implanted with the PEM. In contrast, the PEM
induced downregulation of Bcl-2 expression (Figure 1(d)). It
has been demonstrated that Bim initiates activation of Bax
through a direct interaction in vitro [16]. To confirm the in
vivo interaction between Bax and Bim, tumor lysates from
either control or PEM-treated CFPAC-1 xenograft tumors
were subjected to immunoprecipitation with Bax antibody,
and the bound Bim was detected by immunoblotting. We
found a dose-dependent increase in Bax/Bim binding in the
PEM-implanted tumor lysates (Figure 1(d)).Western blotting
revealed that the PEM induced expression of cleaved caspase-
3, a characteristic of apoptosis, in xenografted tumors
(Figure 1(e)). The immunofluorescence analysis confirmed
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Figure 1: The paclitaxel-eluting membrane (PEM) reduces tumor growth by inducing apoptosis and endoplasmic reticulum- (ER-) stress in
xenografted tumors. (a) The PEM (PTX 10% + Plu) was implanted once the SCK tumor reached 100mm3. Data are presented as means ±
standard deviation (SD). Tumor size wasmeasured at the indicated time points after PEM implantation. (b) Plasma and tumor concentrations
of paclitaxel in SCK tumor-bearing nude mice following PEM implantation for 15 days. Paclitaxel levels in plasma and tumor sections were
determined by LC-MS/MS. Each data point represents the average of five mice ± SD. P, proximal to the PEM; D, distal to the PEM; ∗, lowest
limit of quantification (LLOQ: 15.6 ng/mL). Raw data are shown in the inset. (c) Representative H&E stained PEM-implanted HuCCT-1
tumor. Arrowhead, necrotic tumor cells. (d) The PEM induced apoptosis in CFPAC-1 tumors. CFPAC-1 xenograft tumors were treated with
0, 1, and 5% PEM and implanted for 7 days. BCl-2, Bim, and Bax expression were detected in tumor lysates by Western blotting. Bax and
Bim were immunoprecipitated (IP) with Bax. (e) The PEM induced apoptosis and ER-stress in HuCCT-1, CFPAC-1, and PANC-1 tumors.
Cleaved caspase-3 and CHOP were detected in tumor lysates by Western blotting. (f) Immunofluorescence staining of cleaved caspase-3 in
SCK tumor tissue section from tumor treated with the PEM or control (+Plu). Green, cleaved caspase-3 and blue, nuclei stained with DAPI.
Original magnification, ×40. Scale bar: 50 𝜇m.
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that the PEM increased cleaved caspase-3 expression in
tumors (Figure 1(f)). Because paclitaxel induces mitochon-
drial apoptosis and excess ER stress [18], we examine whether
ER stress was involved in the PEM induced inhibition of
tumor growth. Although the complete mechanism associated
with ER stress-mediated apoptosis is unclear, downstream
ER stress signaling could be correlated with activation of the
c/EBP homology protein (CCAAT-enhancer-binding protein
homologous protein [CHOP], an ER stress marker) [19]. As
shown in Figure 1(e), expression levels of CHOP increased
markedly in tumors implanted with the PEM. These results
indicate that the PEM also inhibited tumor growth via
induction of ER stress in addition to apoptosis.
3.2. The PEM Reduces Growth of Xenografted Tumors in Nude
Mice by Suppressing mTORC1 Signaling and HIF-1 Regulation.
Because the mammalian target of rapamycin complex 1
(mTORC1) signaling pathway is involved in the regulation of
cell growth (e.g., amino acid translation, cell cycle, and angio-
genesis) and tumorigenesis [20–22], we speculated whether
the PEM inhibitedmTORC1 activation status in tumor tissue.
As expected, we found a decrease in phosphorylation of the
mTORC1 targets p70S6K, ribosome protein S6, and eIF4E-
binding protein 1 (4E-BP1) in tumor lysates from tumors
implanted with the PEM compared with those in control
tumors (Figures 2(a) and 2(b)). We also confirmed that total
p70S6K and S6 levels were similar in PEM-implanted and
control tumors (Figures 2(a) and 2(b)). As a result of the inhi-
bition of mTORC1 by the PEM, both HIF-1𝛼 andHIF-1𝛽 pro-
tein levels decreased in PEM-implanted tumors (Figure 2(c)).
Because activation ofHIF-1𝛼 bymTOR is regulated through a
direct interaction between HIF-1𝛼 and regulatory associated
protein of mTOR (Raptor) [23], we determined whether the
PEM blocked the interaction between Raptor and HIF-1𝛼 in
vivo. We performed endogenous immunoprecipitation with
anti-Raptor antibodies followed by the immunodetection
with anti-HIF-1𝛼. The results demonstrated that the PEM
disrupted the Raptor-HIF-1𝛼 interaction in tumors in a dose-
dependent manner (Figure 2(c)). As cyclin B1 is a regulatory
subunit of mitosis-phase promoting factor, and its proper
regulation is essential for the initiation of mitosis [24], we
wondered whether cyclin B1 expression would be reduced by
PEM implantation. As shown in Figure 2(d), cyclin B1 protein
levels were markedly reduced in tumor lysates from PEM-
implanted tumors. Downregulation of cyclin B1 might be
responsible for mitotic arrest and inhibition of tumor growth
by the PEM in the tumor-bearingmice.These results indicate
that the PEM regulates the mitotic phase of the cell cycle, in
part, by suppressing mTORC1 signaling.
3.3. The PEM Reduces CD31 and VEGFR2 Expression in
Tumors. Because the tumor vasculature in xenograft animals
is host-derived, we explored whether PEM implantation as a
method for LDD had any role in vascularization. The gross
assessment of tumors frommice treated with the PEM clearly
showed a pale appearance with reduced vascularization and
tumor volume. In contrast, control tumors appeared larger
and well vascularized (Figure 3(a)). Tumor size and weight
in animals treated with the PEM were significantly lower
(4-5-fold) than those in tumors from controls (data not
shown). To determine whether tumor shrinkage by the
PEM corresponded to inhibited angiogenesis, we assessed
microvascular density in the absence and presence of PEM-
treated tumors by detecting the microvascular marker CD31
[25]. Figures 3(a) and 3(b) show that the PEM downregulated
CD31 protein expression compared with that in control
tumors. To address the signal transduction pathways by
which angiogenesis was inhibited in the PEM-implanted
tumors, VEGF protein levels were measured in tumors
from control or PEM-treated mice by Western blotting.
VEGF protein levels decreased in tumor lysates from PEM-
implanted tumors (Figure 3(c)). Although VEGF protein lev-
els decreased slightly, PEM implantation induced downreg-
ulation of the VEGFR2 protein in a dose-dependent manner
in SCK tumors (Figure 3(c)). The immunofluorescence anal-
ysis confirmed that VEGFR2 protein expression decreased
significantly in tumors from PEM-implanted mice, which
was paralleled by reduced tumor vessel density (Figure 3(b)).
Angiogenesis within the tumor microenvironment is a com-
plex process regulated by pro- and antiangiogenic factors
produced by both tumor cells and the stromal compartment
[26].We wondered whether PEM-mediated antiangiogenesis
was caused by changes in VEGFR2 downstream signaling
molecules. We found that PEM-implanted tumors exhibited
decreased levels of matrix metalloproteinase 2 [27], an extra-
cellular matrix (ECM) degrading component, compared with
those in control tumors (Figure 3(e)). Expression of CD44
[28], which mediates cell-cell and cell-matrix interactions,
secreted protein acidic and rich in cysteine (SPARC) [29],
a stromal cell marker, and vimentin [30], a mesenchymal
marker, decreased in PEM-implanted tumors relative to those
in control tumors (Figure 3(e)). Taken together, these results
suggest that decreasing tumor vasculature can limit the
supply of nutrients and oxygen to tumor cells, thereby leading
to antitumor effects. These findings indicate that the PEM
inhibited angiogenesis by downregulating VEGF, VEGFR2,
vascularization, and tumor-stromal interaction-related pro-
tein expression.
4. Discussion
We investigated protein profiles in whole tumors from
pancreatic/cholangiocarcinoma xenografted tumor-bearing
mice after PEM implantation to investigate the molecular
mechanisms behind the paclitaxel-eluting stent for LDD and
attenuation of tumor growth in a malignant biliary obstruc-
tion. Drug-eluting stent might ideally be used to treat the
extrahepatic bile duct cancer that grows in the lining of the
bile ducts. Unlike biliary cancer, a malignant biliary obstruc-
tion with pancreatic cancer, which occurs from extrinsic
compression, lacks rationale for utilizing paclitaxel-eluting
stent implants. However, MSCPM-II could be expected to
have an antitumor effect by suppressing tumor in-growth
from a combination of systemic or radiation treatment. Inno-
vative strategies for local and prolonged delivery of approved
chemotherapeutic drugs (e.g., paclitaxel) fromMSCPM-II in
patients with inoperable malignant biliary obstruction are
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Figure 2: Paclitaxel-eluting membrane (PEM) implantation inhibits mTORC1 activation and hypoxia-inducible factor (HIF)-1 regulation
in xenografted tumors. (a) Western blotting of phospho-S6K, S6K, phospho-S6, S6, phospho-4EBP1, and 4EBP1 expression levels in tumor
lysates from HuCCT-1 tumors implanted with the PEM or control (+Plu) (left). Relative quantification of phosphoprotein expression levels
is shown in the control (gray bars) or PEM (black bars) implanted tumors. Values are corrected for corresponding total antibody protein
∗∗
𝑃 < 0.01; ∗∗∗𝑃 < 0.001 (right). (b) Western blotting of phospho-S6K and S6K expression levels in tumor lysates from indicated tumors
from the PEM-implanted or control groups (left) and relative quantification of phospho-S6K expression levels ∗∗∗𝑃 < 0.001 (right). (c)
Western blot of HIF-1𝛼 and HIF-1𝛽 in a protein extract from indicated tumors implanted with the PEM or control for 20 days (left). SCK
xenograft tumors were treated with 0, 5, and 10% PEM and implanted for 7 days. Tumor protein lysates were prepared and analyzed for Raptor
and HIF-1𝛼 protein expression. Immunoprecipitation and Western blotting were used to detect the endogenous Raptor-HIF-1𝛼 interaction
(right). (d)Western blotting analysis of cyclin B1 expression levels in tumor lysates from indicated tumors treated with various concentrations
of PEM (SCK, 0, 5, and 10%; CFPAC-1, 0, 1, and 5%).
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Figure 3: Paclitaxel-elutingmembrane (PEM) implantation attenuates angiogenesis in xenografted tumors. (a) Representative photographs of
the grossmorphology of SCK tumors from nudemice implanted with the PEMor control (+Plu)membrane for 7 days. ∗, tumor; arrow, PEM;
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PEM or control. (b) Representative immunofluorescence analysis for CD31 in SCK tumors implanted with the PEM or control. Graph shows
relative fluorescence intensity of CD31 (right). (c) PEM implantation decreased VEGF expression in tumor lysates from indicated tumors
(upper). VEGFR2 expression was evaluated in SCK tumor tissue after implantation with 0, 5, and 10% paclitaxel in a PEM by immunoblotting
(lower). (d) Representative immunofluorescence analysis for VEGFR2 in tissue from SCK tumors implanted with the PEM or control and
relative fluorescence intensity ofVEGFR2 (right). ((b), (d)) Positive protein staining is in green and nuclei are stained bluewithDAPI.Original
magnification, ×40. Scale bar: 50 𝜇m. Values are means ± standard deviation (SD). 𝑁 = 9 fields per group. ∗∗𝑃 < 0.01. (e) Effects of PEM
implantation on the expression of MMP-2, CD44, SPARC, and vimentin proteins in indicated tumors. Proteins were detected by Western
blotting using the indicated antibodies.
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currently under investigation. Local application of a chemo-
therapeutic agent in a stent can minimize the systemic side
effects of the agent whilemaximizing its concentrationwithin
the bile duct.Here, we show that the PEM is a LDDdevice that
supplies paclitaxel to tumors and inhibits their growth.
The hallmarks of cancers are deregulation of the cell
cycle machinery, self-sufficiency of growth signals, insen-
sitivity to growth inhibitory signals, evasion of apoptosis,
tissue invasion, metastasis, and sustained angiogenesis [31].
Tumor progression requires angiogenesis, which is generally
induced in response to hypoxia through a process known
as the angiogenic switch [32–35]. In this study, we showed
that the cancer signal transduction pathways were changed
by the PEM implanted in pancreatic/cholangiocarcinoma
xenografted tumors.
mTORC1 contains Raptor, which serves as a scaffolding
protein for recruiting substrates for phosphorylation by the
mTORC1kinase domain [36]. Activated mTORC1 regulates
protein synthesis by directly phosphorylating S6K and 4E-
BP1, which are translation-initiating factors important for
cap-dependent mRNA translation and to increase the level of
proteins needed for cell cycle progression, proliferation, and
angiogenesis [37–39]. Notably, PEM implantation induced
downregulation of mTORC1, dephosphorylated phospho-
S6K, phospho-S6, and phospho-4E-BP1 and inhibited the
protein synthesis required for angiogenesis and tumor
growth.
Because tumor growth and metastasis are highly depen-
dent on increased microvascular density, a reduction in the
number of blood vessels is critical for antitumor responses.
VEGF-VEGFR2 signal transduction leads to activation of
various downstream signaling molecules responsible for
endothelial cellmigration, proliferation, and survival [25, 40].
Among the many changes in protein function that occur
during tumor progression, alterations in cell-cell and cell-
matrix adhesion seem to play a central role in facilitating
tumor cell migration, invasion, and metastasis [41]. As
expected, PEM implantation prevented tumor growth by
affecting vascularization in both the pancreatic and cholan-
giocarcinoma models. We also observed that PEM implan-
tation into xenograft tumors inhibited tumor growth by dis-
rupting tumor invasion and metastatic behaviors, including
the epithelial-to-mesenchymal transition and breakdown of
the ECM. Therefore, the PEM induced inhibition of tumor
growth in the xenografted tumor models might be explained
by a combination of several mechanisms of action, such as
antiproliferative, proapoptotic, and antiangiogenic effects.
The limitations of this study should be discussed. Because
an orthotopic animal model of malignant biliary obstruction
is not available so far, we should have investigated the molec-
ular mechanism of the antitumor effect by the PEM as a LDD
in subcutaneous xenografted nude mice. Although several
strategies (e.g., fluorescent tagging and radioisotope labeling
methods) have been developed to evaluate the distribution,
penetration and distribution of a drug from a drug-eluting
membrane into tumors remain a major challenge in cancer
chemotherapy because distribution is impeded by several
factors related to the physicochemical characteristics of the
drug and the tumor tissue. Further investigations are needed
to determine the mode of drug distribution from a drug-
eluting membrane into tumors. Paclitaxel is suitable as a
chemotherapeutic agent in a drug-eluting stent due to its
lipophilic character and broad-spectrum anticancer effects,
but gemcitabine is clinically preferred for treating a malig-
nant biliary obstruction; thus, further improvements in
hydrophilic agents (e.g., gemcitabine) for use in drug-eluting
stents should be investigated.
5. Conclusion
We report that local delivery of paclitaxel from a PEM inhib-
ited growth of inoculated pancreatic cancer and cholangio-
carcinoma in nude mice by suppressing angiogenesis via the
mTORC1/inducing apoptosis signaling pathway. The under-
standing of the molecular mechanisms behind the paclitaxel-
eluting stent will change the paradigm for more successful
treatment of patients with malignant biliary obstructions.
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